Biocare Medical and Bethyl Laboratories Announce the Launch of TIGIT IVD Rabbit Monoclonal Antibody for Immunohistochemical Applications
August, 4 2020 – Biocare Medical LLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories, announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.
TIGIT plays an important role in transplantation tolerance and tumor immune surveillance. Several studies indicate that TIGIT exhibits a synergistic function with the PD-1/PD-L1 pathway in the inhibition of T cell proliferation. The use of TIGIT, in conjunction with other checkpoint receptors, such as PD-1, has shown to be a promising marker for immunotherapy.
"We are excited for the release of an IVD grade TIGIT [BL074F] antibody for clinical application; the Bethyl clone [BLR047F] has been shown to display high sensitivity and specificity based on our internal research," said Dr. Jason Ramos, Vice President – Reagent Research and Development at Biocare Medical.
We believe that our new TIGIT IVD antibody will be a cost-effective IHC solution to the pharmaceutical and biotech research institutions requiring an IVD grade quality in early-stage research and companion diagnostics development.
TIGIT [BLR047F] is an IVD antibody available in a concentrate format to support titration by end-users as well as a ready-to-use predilute format. TIGIT [BLR047F] antibody is commercially available for immediate sale within the domestic US and European Union.
Fortis partners with diagnostics and life sciences companies to custom-design, validate, and manufacture proprietary solutions to solve their most difficult development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America. To learn more about Fortis, please visit www.fortislife.com.
